Land: New Zealand
Sprog: engelsk
Kilde: Medsafe (Medicines Safety Authority)
Fluorouracil 50 mg/mL; ;
Pfizer New Zealand Limited
Fluorouracil 50 mg/mL
50 mg/mL
Solution for injection
Active: Fluorouracil 50 mg/mL
Vial, 5 x 5mL pack, 5 dose units
Prescription
Prescription
Chemische Fabrik Berg GmbH
DBL® Fluorouracil Injection B.P. is indicated alone or in combination for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. Fluorouracil should only be used when other proven measures have failed or are considered impractical.
Package - Contents - Shelf Life: Vial, 5mL - 5 dose units - 18 months from date of manufacture stored Store at 8-25°C, do not refrigerate. Protect from light - Vial, 10mL - 5 dose units - 24 months from date of manufacture stored Store at 8-25°C, do not refrigerate. Protect from light - Vial, glass, 50ml - 1 dose units - 24 months from date of manufacture stored Store at 8-25°C, do not refrigerate. Protect from light - Vial, glass, 20ml - 5 dose units - 24 months from date of manufacture stored Store at 8-25°C, do not refrigerate. Protect from light
1986-08-27
Version: pfdfluoi10221 Supersedes: hhdfluoi10720 Page 1 of 14 NEW ZEALAND DATA SHEET 1. PRODUCT NAME DBL ™ Fluorouracil 25 mg/ml Solution for Injection. DBL ™ Fluorouracil 50 mg/ml Solution for Injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of DBL Fluorouracil containing 25 mg or 50 mg of fluorouracil. DBL Fluorouracil is a sterile preservative free solution of 5-Fluorouracil in Water for Injection, prepared with the aid of Sodium Hydroxide. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. DBL Fluorouracil Injection is a clear, colourless to slightly yellow solution. The pH of the solution is approximately 8.9. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DBL Fluorouracil Injection is indicated alone or in combination for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. Fluorouracil should only be used when other proven measures have failed or are considered impractical. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSE The dosage being based on the patient's actual weight. Ideal weight is used only if the patient is obese or if there has been a spurious weight gain due to oedema, ascites or other forms of abnormal fluid retention. The total daily dose of fluorouracil should not exceed 1 gram. The initial recommended doses should be reduced by one third to a half if any of the following conditions are present: 1. poor nutritional state. Version: pfdfluoi10221 Supersedes: hhdfluoi10720 Page 2 of 14 2. after major surgery (within previous 30 days). 3. inadequate bone marrow function (W.B.C. count less than 5,000 per mm³; platelet count less than 100,000 per mm 3 ). 4. impaired hepatic and/or renal function. The following regimes have been recommended for use of fluorouracil as a single agent in adults: _INTRAVENOUS INFUSION _ 15 mg/kg bodyweight (to a maximum of 1 g daily) diluted Læs hele dokumentet